RSPR-007 Mannitol Challenge Trial
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
CRD007
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- Written informed consent
- Age ≥18 and <50 years
- Diagnosis of asthma
Exclusion Criteria:
- Clinical significant comorbidities
- Lower respiratory tract infection <6 weeks prior to Visit 1
- Others, as specified in the protocol
Sites / Locations
- Hvidovre Hospital
- Bisbebjerg Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Active Comparator
Active Comparator
Arm Label
Placebo
CRD007 Low dose
CRD007 High dose
Arm Description
Matching placebo tables are given as a single dose
"Low dose" of CRD007 (pemirolast sodium) given as a single dose
"High dose" CRD007 (pemirolast sodium) given as a single dose
Outcomes
Primary Outcome Measures
PD15 for mannitol after treatment with CRD007 and placebo
The FEV1 value taken after the 0 mg capsule is taken as pre-challenge FEV1 and used to calculate the percentage decrease in FEV1 in response to the mannitol challenge. The test ends when the FEV1 has fallen by 15% or more (PD15)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02609334
Brief Title
RSPR-007 Mannitol Challenge Trial
Official Title
A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Trial, Investigating the Efficacy of CRD007 in Adult Subjects With Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
March 2015 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RSPR Pharma AB
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a double-blind, randomised, placebo-controlled, cross-over, Phase 2 trial evaluating two doses (a low and a high) of CRD007 for the treatment of asthmatic trial subjects with a positive asthma test (mannitol challenge) prior to enrolment.
Detailed Description
The present trial will include subjects with diagnosed asthma in a provocation model which mimics assessments of asthma control. Mannitol challenge is an indirect asthma provocation test, which requires the presence of inflammatory cells, particularly mast cells, in the airways.
The trial involved in total 5 subject visits and will last for a maximum of 30 days for each subject from Visit 2 (Randomisation) to Visit 5 (Follow up).
Visit 2,3, and 4 will be treatment visits where Investigational Medicinal Product (IMP) is administrated 3 hours before the Mannitol challenge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo tables are given as a single dose
Arm Title
CRD007 Low dose
Arm Type
Active Comparator
Arm Description
"Low dose" of CRD007 (pemirolast sodium) given as a single dose
Arm Title
CRD007 High dose
Arm Type
Active Comparator
Arm Description
"High dose" CRD007 (pemirolast sodium) given as a single dose
Intervention Type
Drug
Intervention Name(s)
CRD007
Other Intervention Name(s)
Pemirolast sodium
Intervention Description
One single dose given 3 hours prior to Mannitol challenge
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
One single dose given 3 hours prior to Mannitol challenge
Primary Outcome Measure Information:
Title
PD15 for mannitol after treatment with CRD007 and placebo
Description
The FEV1 value taken after the 0 mg capsule is taken as pre-challenge FEV1 and used to calculate the percentage decrease in FEV1 in response to the mannitol challenge. The test ends when the FEV1 has fallen by 15% or more (PD15)
Time Frame
Forced expiratory volume at one second (FEV1) manoeuvres are performed 60 seconds after each dose
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent
Age ≥18 and <50 years
Diagnosis of asthma
Exclusion Criteria:
Clinical significant comorbidities
Lower respiratory tract infection <6 weeks prior to Visit 1
Others, as specified in the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vibeke Backer, MD
Organizational Affiliation
Bispebjerg Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hvidovre Hospital
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
Facility Name
Bisbebjerg Hospital
City
København NV
ZIP/Postal Code
2400
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
RSPR-007 Mannitol Challenge Trial
We'll reach out to this number within 24 hrs